Roche projects mid-single digit group sales growth in 2025, with core EPS growth in the high-single digit range. The company expects a CHF1.2 billion impact from the loss of exclusivity but aims to ...

"The ongoing complexities of COVID-19 require multiple lines of defence," said Bill Anderson, CEO of Roche Pharmaceuticals. “By joining forces with Atea, we hope to offer an additional treatment ...

Roche Holding AG is a research healthcare company. It operates through the Pharmaceuticals and Diagnostics segments. The Pharmaceutical division comprises the business segments, such as Roche ...